ArticleOncology research2026
Comprehensive Bioinformatics Analysis and Experimental Verification RNF186 Is a Recurrence Signature Gene of Hepatocellular Carcinoma that Promotes Cell Proliferation.
Article in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Tumor recurrence is a major determinant of poor prognosis in hepatocellular carcinoma (HCC), yet its cellular and molecular basis remains incompletely understood. This study aimed to identify recurrence-associated genes at single-cell resolution and to develop a prognostic model for predicting survival outcomes and immunotherapy responsiveness in HCC. Methods: Single-cell RNA sequencing data from 12 primary and 6 recurrent HCC samples were integrated and analyzed to identify genes characteristic of recurrence. After quality control, principal component analysis, and t-SNE-based clustering were used to identify highly variable genes for cell clustering and annotation. Based on macrophage characteristic genes, a recurrence-related risk score was constructed using a LASSO-Cox regression model, and a nomogram integrating clinical variables was developed. Prognostic performance was assessed using Kaplan-Meier analysis and time-dependent ROC curves. Immune infiltration profiling was performed to compare immune characteristics between risk groups defined by the prognostic model. Multivariate Cox regression was applied to identify independent prognostic biomarkers, which were subsequently validated by cell function experiments. Results: The risk model effectively stratified patients into high- and low-risk groups with distinct survival outcomes, demonstrating high predictive accuracy for 1-, 3-, and 5-year survival. High-risk patients showed altered immune profiles and a reduced predicted response to immunotherapy. GRID2, RNF186, and SLC4A10 were identified as independent prognostic genes, with RNF186 promoting HCC cell proliferation in a SESN2-dependent manner. Conclusion: This prognostic model provides new insights into precision medicine and immunotherapy for HCC, highlighting the potential clinical significance of RNF186 as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.